Product Description
Mechanisms of Action: CDK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eisai
Company Location: BUNKYO-KU TOKOYO 112 M0
Company CEO: Haruo Naito
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Colorectal Cancer|Breast Cancer|Renal Cell Carcinoma|Adenocarcinoma|Gastrointestinal Cancer|Melanoma|Myelodysplastic Syndrome|Preleukemia
Phase 1: Oncology Solid Tumor Unspecified|Pancreatic Cancer|Gastrointestinal Cancer|Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCI-2012-02065 | P2 |
Completed |
Myelodysplastic Syndrome|Preleukemia |
2017-06-07 |
|
| E7070-A001-106 | P1 |
Completed |
Pancreatic Cancer|Gastrointestinal Cancer|Lung Cancer |
2013-03-01 |
|
| E7070-J081-217 | P2 |
Terminated |
Gastrointestinal Cancer |
2006-07-01 |
|
| 2004-002597-33 | P2 |
Completed |
Colorectal Cancer |
2006-01-10 |
|
| 2004-000774-31 | P2 |
Completed |
Breast Cancer |
2005-06-24 |
|
| Stage IV | P2 |
Completed |
Melanoma |
2001-11-01 |
|
| E7070-E044-209 | P2 |
Completed |
Colorectal Cancer |
None |
|
| E7070-A001-211 | P2 |
Completed |
Breast Cancer |
None |
|
| EORTC-16973 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
None |
|
| E7070-A001-206 | P2 |
Completed |
Renal Cell Carcinoma|Adenocarcinoma |
None |
|
| EORTC-16975 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
None |
|
| E7070-E044-213 | P2 |
Terminated |
Breast Cancer |
None |
|
| E7070-E044-214 | P2 |
Completed |
Colorectal Cancer |
None |